Ovid Therapeutics (OVID) Accounts Payables (2016 - 2026)

Ovid Therapeutics (OVID) has reported Accounts Payables for 11 consecutive years, with $4.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables rose 3.09% year-over-year to $4.1 million; the trailing twelve-month figure through Jun 2026 stood at $4.1 million (up 3.09% YoY), and the FY2025 full-year result was $2.0 million, down 38.72% from the prior year.
• Accounts Payables declined to $4.1 million in Q2 2026 per OVID's latest filing, from $8.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $8.9 million in Q1 2026 and bottomed at $1.0 million in Q3 2022.
• Historically, Accounts Payables has averaged $3.2 million across 5 years, with a median of $3.0 million in 2024.
• The widest YoY moves for Accounts Payables: up 407.58% in 2022, down 72.6% in 2022.
• Over 5 years, Accounts Payables stood at $2.0 million in 2022, then jumped by 89.61% to $3.7 million in 2023, then decreased by 13.8% to $3.2 million in 2024, then tumbled by 38.72% to $2.0 million in 2025, then surged by 108.18% to $4.1 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $4.1 million, $8.9 million, and $2.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.